NearWave develops non-invasive devices using frequency domain near infrared spectroscopy to assess vital biomarkers like tissue oxygen saturation and hemoglobin concentrations.
Founded
2022
Revenue
$0-968K
Company Stage
Seed
YC Batch
W22
Product Features & Capabilities
NearWave Scanner, non-invasive device, frequency domain near infrared spectroscopy (fdNIRS), measures tissue oxygenation, assesses StO2, HHb, HbO2, and THb, applicable in sports medicine, weight loss, cardiovascular health assessment.
